BFG
XERS icon

Bleakley Financial Group’s Xeris Biopharma Holdings XERS Stock Holding History

Bleakley Financial Group’s Portfolio XERS Stock Details XERS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-10,536
Closed -$35.7K – 1031
2024
Q4 		$35.7K Sell
10,536
-580
-5% -$1.87K ﹤0.01% 1032
2024
Q3 		$31.7K Sell
11,116
-1,040
-9% -$2.67K ﹤0.01% 1011
2024
Q2 		$27.4K Buy
+12,156
New +$24.5K ﹤0.01% 1000
2023
Q4 		– Sell
-11,048
Closed -$20.5K – 979
2023
Q3 		$20.5K Buy
+11,048
New +$25.3K ﹤0.01% 872

Other funds holding XERS

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
RA
Rosalind Advisors Toronto, Ontario, Canada $249M AUM 80.12% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
N
Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return

Bleakley Financial Group's XERS Position: Q1 2025 in Review

Bleakley Financial Group sold out of Xeris Biopharma Holdings (XERS) in Q1 2025, closing a stake of 10,536 shares — an estimated $35.7K sold.

Bleakley Financial Group first reported a position in XERS in Q3 2023 and held it in 4 quarters. The position peaked at $35.7K in Q4 2024. 199 funds tracked by Wall St. Rank hold XERS as of Q1 2025.

  • Bleakley Financial Group reported no remaining Xeris Biopharma Holdings position as of Q1 2025 after selling out during the quarter.
  • Bleakley Financial Group sold 10,536 Xeris Biopharma Holdings shares in Q1 2025, an estimated $35.7K.
  • Bleakley Financial Group first reported a position in Xeris Biopharma Holdings in Q3 2023 and held it in 4 quarters.
  • Bleakley Financial Group's Xeris Biopharma Holdings position peaked at $35.7K in Q4 2024.
  • 199 funds tracked by Wall St. Rank held Xeris Biopharma Holdings as of Q1 2025.

Based on Bleakley Financial Group's 13F filing for Q1 2025, filed 1 May 2025.